Leukogene Therapeutics Inc.
Biotechnology company developing MHC class II-targeted recombinant protein immunotherapies that conjugate tumor-associated antigens to direct and mobilize the immune system against difficult-to-treat cancers. Headquartered in Charleston, SC, and originating as a spin-out from the Medical University of South Carolina (MUSC), the company advances candidates from discovery and preclinical proof-of-concept toward first-in-human clinical development.
Industries
N/A
Products
MHCII-targeted recombinant protein candidate directed at CD33
A recombinant protein therapeutic that conjugates a CD33 tumor-associated antigen to an MHC class II-targeting moiety developed as a clinical candidate for acute myelogenous leukemia and related hematologic malignancies.
MHCII-targeted recombinant protein candidate directed at mesothelin
A recombinant protein therapeutic that conjugates a mesothelin tumor-associated antigen to an MHC class II-targeting moiety developed for pancreatic ductal adenocarcinoma and other solid tumors expressing mesothelin.
MHCII-targeted recombinant protein candidate directed at CD33
A recombinant protein therapeutic that conjugates a CD33 tumor-associated antigen to an MHC class II-targeting moiety developed as a clinical candidate for acute myelogenous leukemia and related hematologic malignancies.
MHCII-targeted recombinant protein candidate directed at mesothelin
A recombinant protein therapeutic that conjugates a mesothelin tumor-associated antigen to an MHC class II-targeting moiety developed for pancreatic ductal adenocarcinoma and other solid tumors expressing mesothelin.
Services
Collaborative preclinical development and translational partnerships
Partnered preclinical research and translation of antigen-targeted immunotherapies with academic and industry collaborators.
CMC and project management for biologic candidates
Project leadership and CMC support to advance biologic therapeutics from development toward clinical readiness.
Collaborative preclinical development and translational partnerships
Partnered preclinical research and translation of antigen-targeted immunotherapies with academic and industry collaborators.
CMC and project management for biologic candidates
Project leadership and CMC support to advance biologic therapeutics from development toward clinical readiness.
Expertise Areas
- Cancer immunotherapy
- Recombinant protein therapeutics
- Protein engineering and biochemistry
- Preclinical oncology models and translational research
Key Technologies
- Recombinant protein therapeutics
- MHC class II targeting
- Tumor-associated antigen conjugation
- Protein engineering